• Home
• Corporate Profile
  • Overview
  • History
  • Mission and Values
  • Senior Management
  • Board of Directors
  • Clinical Advisory Board
  • Clinical Steering Committee
• Product Development
  • Overview
  • Cardiovascular Disease
    • Atherosclerosis
    • ApoA-I
  • Technology Platform
    • NexVas™ Animation
    • NexVas™ Plaque Regression
      • Lead Drug RVX-208
    • Autoimmune Drug Development Program
    • NexVas™ Alzheimer's Disease
  • ReVas™ Program
  • Clinical Trials
    • Completed Clinical Trials
  • Product Pipeline
  • Glossary
• Partnering
  • Overview
  • Opportunities
• Investors
  • Overview
  • Stock Info
  • Investor Documents
  • Analyst Coverage
  • FAQs
  • Investor Contact
• Media
  • Overview
  • Press Releases
  • Fact Sheets
  • Events
  • Image Library
  • Awards & Recognition
  • Media Contact
• Careers
  • Overview
  • Benefits
  • Current Opportunities
• Contact Us
  • Request to be contacted

• Overview
• Press Releases
• Fact Sheets
• Events
• Image Library
• Awards & Recognition
• Media Contact

Fact Sheets

© 2012 Resverlogix Corp. | Legal Notice | handcrafted by nonfiction

This page was last updated on: September 27, 2011